# Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy

> **NCT04130542** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Lyvgen Biopharma Holdings Limited** · enrollment: 276 (estimated)

## Conditions studied

- Cancer

## Interventions

- **BIOLOGICAL:** LVGN6051
- **BIOLOGICAL:** KEYTRUDA® (pembrolizumab)

## Key facts

- **NCT ID:** NCT04130542
- **Lead sponsor:** Lyvgen Biopharma Holdings Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-10-31
- **Primary completion:** 2025-12-31
- **Final completion:** 2025-12-31
- **Target enrollment:** 276 (ESTIMATED)
- **Last updated:** 2024-10-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04130542

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04130542, "Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04130542. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*